ArticleBMC cancer2018
International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Liquid biopsy in malignant primary bone tumors: Clinical applications of circulating tumor DNA and circulating tumor cells for diagnosis, prognosis and treatment monitoring (Review).Oncology reports · 2026Review
- Circulating tumor DNA in patients with cancer: insights from clinical laboratory.Advances in laboratory medicine · 2025Review
- Article
- Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS).Journal of experimental & clinical cancer research : CR · 2025Article
- Article
- Liquid biopsy to personalize treatment for metastatic prostate cancer.American journal of translational research · 2024Review
- Analysis of the primary factors influencing donor derived cell-free DNA testing in kidney transplantation.Frontiers in immunology · 2024Review
- The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
- Cell-free DNA in the management of prostate cancer: Current status and future prospective.Asian journal of urology · 2023Review
- Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring.Healthcare (Basel, Switzerland) · 2022Article
- Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.Virchows Archiv : an international journal of pathology · 2022Review
- Results of a worldwide external quality assessment of cfDNA testing in lung Cancer.BMC cancer · 2022Article
- Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.ESMO open · 2022Review
- A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2022Review
- The International Collaboration for Cancer Classification and Research.International journal of cancer · 2021Article
- A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies.PloS one · 2021Article
- Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study.Cancers · 2020Article
- The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review.Cancers · 2020Review
- Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.Cancer metastasis reviews · 2020Review
- External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants.Pathology oncology research : POR · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMolecular analysis of circulating tumour DNA (ctDNA) is becoming increasingly important in clinical treatment decisions. A pilot External Quality Assessment (EQA) scheme for ctDNA analysis was organized by four European EQA providers under the umbrella organization IQN Path, in order to investigate the feasibility of delivering an EQA to assess the detection of clinically relevant variants in plasma circulating cell-free DNA (cfDNA) and to analyze reporting formats.
methodsThirty-two experienced laboratories received 5 samples for EGFR mutation analysis and/or 5 samples for KRAS and NRAS mutation analysis. Samples were artificially manufactured to contain 3 mL of human plasma with 20 ng/mL of fragmented ctDNA and variants at allelic frequencies of 1 and 5%.
resultsThe scheme error rate was 20.1%. Higher error rates were observed for RAS testing when compared to EGFR analysis, for allelic frequencies of 1% compared to 5%, and for cases including 2 different variants. The reports over-interpreted wild-type results and frequently failed to comment on the amount of cfDNA extracted.
conclusionsThe pilot scheme demonstrated the feasibility of delivering a ctDNA EQA scheme and the need for such a scheme due to high error rates in detecting low frequency clinically relevant variants. Recommendations to improve reporting of cfDNA are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.